Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa
and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma …

Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the
blood coagulation pathway leading to thrombin generation and clot formation. It is selective …

The activated serine protease factor Xa is a promising target for new anticoagulants. After
studies on naturally occurring factor Xa inhibitors indicated that such agents could be effective …

… thromboplastin time c, and HepTest d. Subjects received study drug on day 0 and days 3–7 …
thromboplastin time c, and HepTest d. Subjects received study drug on day 0 and days 3–7 …

Background and Objective There is a clinical need for new oral anticoagulants to prevent
and treat thromboembolic diseases. Given its integral role in the coagulation cascade, factor …

Rivaroxaban is a novel, oral, direct factor Xa inhibitor for the prevention and treatment of
thromboembolic disorders. The objective of this study was to investigate the in vivo metabolism …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Prior to the commencement of this
study, it was already known that rivaroxaban is partially cleared via the kidneys and an …

The pharmacokinetics of moxifloxacin were investigated in six studies after oral administration
of 50, 100, 200, 400, 600, and 800 mg. Eight healthy male volunteers were included in …

Aims The anticoagulant rivaroxaban is an oral, direct F actor X a inhibitor for the management
of thromboembolic disorders. Metabolism and excretion involve cytochrome P450 3A4 ( …

Anticoagulants are often dose adjusted, or their use restricted, in patients with extremes of
body weight. Rivaroxaban (BAY 59‐7939) is a novel, oral, direct factor Xa inhibitor in clinical …